Document Detail

Adverse effects of denileukin diftitox and their management in patients with cutaneous T-cell lymphoma.
MedLine Citation:
PMID:  23022942     Owner:  NLM     Status:  MEDLINE    
Cutaneous T-cell lymphoma (CTCL) is a rare non-Hodgkin lymphoma with predominant skin manifestations and a relatively indolent course at early stages, but it can be fatal in advanced settings. In the absence of cure, the goal of therapy for CTCL is to induce long-term remissions without further compromising a patient's immune system or quality of life. Denileukin diftitox (DD) is a fusion protein chemotherapeutic agent used for the treatment of persistent or recurrent CTCL. It binds selectively to the high- and intermediate-affinity interleukin-2 receptor (CD25+) on lymphocytes and is internalized by these cells. Inside the cells, the diphtheria toxin portion of fusion protein is cleaved by proteolytic enzymes, causing cell death. DD produces durable responses and may forestall disease progression. This article reviews DD phase III clinical trial data and summarizes one institution's clinical experience in the management of the most frequent and clinically significant adverse effects of DD (e.g., acute infusion reactions, capillary leak syndrome, hypoalbuminemia, visual changes, constitutional symptoms, rash, hepatobiliary disorders). Many DD-associated adverse effects can be managed effectively without dose reduction or interruption of treatment with prudent use of supportive care measures.
Sue McCann; Oleg E Akilov; Larisa Geskin
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Clinical journal of oncology nursing     Volume:  16     ISSN:  1538-067X     ISO Abbreviation:  Clin J Oncol Nurs     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-01     Completed Date:  2013-03-06     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  9705336     Medline TA:  Clin J Oncol Nurs     Country:  United States    
Other Details:
Languages:  eng     Pagination:  E164-72     Citation Subset:  N    
Department of Dermatology, University of Pittsburgh, Pennsylvania, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / adverse effects*,  therapeutic use
Clinical Trials, Phase III as Topic
Diphtheria Toxin / adverse effects*,  therapeutic use
Interleukin-2 / adverse effects*,  therapeutic use
Lymphoma, T-Cell / drug therapy*
Recombinant Fusion Proteins / adverse effects,  therapeutic use
Skin Neoplasms / drug therapy*
Reg. No./Substance:
0/Antineoplastic Agents; 0/Diphtheria Toxin; 0/Interleukin-2; 0/Recombinant Fusion Proteins; 25E79B5CTM/denileukin diftitox

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The Use of Motivational Interviewing to Promote Peer-to-Peer Support for Cancer Survivors.
Next Document:  Pilot study of "miracle fruit" to improve food palatability for patients receiving chemotherapy.